Doxercalciferol

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Doxercalciferol
Doxercalciferol.svg
Names
IUPAC name
(1S,3R,5Z,7E,22E)-9,10-Secoergosta-5,7,10,22-tetraene-1,3-diol
Other names
1-Hydroxyergocalciferol; 1-Hydroxyvitamin D2; 1α-Hydroxyergocalciferol; 1α-Hydroxyvitamin D2; Hectorol; TSA 840
Identifiers
3D model (JSmol)
ChEBI
ChEMBL
ChemSpider
DrugBank
ECHA InfoCard 100.170.997
UNII
Properties
C28H44O2
Molar mass 412.658 g·mol−1
Pharmacology
H05BX03 (WHO)
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is ☑Y☒N ?)
Infobox references

Doxercalciferol (or 1-hydroxyergocalciferol, trade name Hectorol) is drug for secondary hyperparathyroidism and metabolic bone disease.[1] It is a synthetic analog of ergocalciferol (vitamin D2). It suppresses parathyroid synthesis and secretion.[2]

Docercalciferol is the Vitamin D2 analogue of alfacalcidol.[3] It undergoes 25-hydroxylation in the liver to become the active ercalcitriol, without the involvement of kidneys.[4]

References[edit]

  1. ^ Sprague S M; Ho L T (2002). "Oral doxercalciferol therapy for secondary hyperparathyroidism in a peritoneal dialysis patient". Clinical nephrology. 58 (2): 155–160. PMID 12227689.
  2. ^ "Doxercalciferol". Drugs.com.
  3. ^ Upton, R. A.; Knutson, J. C.; Bishop, C. W.; LeVan, L. W. (1 April 2003). "Pharmacokinetics of doxercalciferol, a new vitamin D analogue that lowers parathyroid hormone". Nephrology Dialysis Transplantation. 18 (4): 750–758. doi:10.1093/ndt/gfg030.
  4. ^ "HECTOROL INJECTION (doxercalciferol)" (PDF). FDA accessdata. Retrieved 21 April 2018.